Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate Presented in part at the 39th annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30–June 3, 2003.
dc.contributor.author | Mackler, Niklas J. | en_US |
dc.contributor.author | Dunn, Rodney L. | en_US |
dc.contributor.author | Hellerstedt, Beth | en_US |
dc.contributor.author | Cooney, Kathleen A. | en_US |
dc.contributor.author | Fardig, Judith | en_US |
dc.contributor.author | Olson, Karin B. | en_US |
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.contributor.author | Smith, David C. | en_US |
dc.date.accessioned | 2007-07-11T18:13:58Z | |
dc.date.available | 2007-07-11T18:13:58Z | |
dc.date.issued | 2006-06-15 | en_US |
dc.identifier.citation | Mackler, Niklas J.; Dunn, Rodney L.; Hellerstedt, Beth; Cooney, Kathleen A.; Fardig, Judith; Olson, Karin; Pienta, Kenneth J.; Smith, David C. (2006). "Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate Presented in part at the 39th annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30–June 3, 2003. ." Cancer 106(12): 2617-2623. <http://hdl.handle.net/2027.42/55222> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55222 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16691618&dopt=citation | en_US |
dc.description.abstract | BACKGROUND The primary objective of the current study was to identify the tolerable dose level of oral vinorelbine when given in combination with estramustine to men with hormone-refractory prostate cancer (HRPC). The secondary objectives were to describe the toxicities of the combined regimen in patients with HRPC and to estimate the efficacy of oral vinorelbine in combination with estramustine based on the prostate-specific antigen (PSA) response. METHODS Thirty-three patients with HRPC were treated on a 28-day cycle with estramustine at a dose of 140 mg orally 3 times a day on Days 1-3 and 8-10. Vinorelbine was given orally on Days 2 and 9. The initial dose of vinorelbine was 50 mg/m 2 and was escalated to 70 mg/m 2 using the time-to-event continual reassessment method. RESULTS Three of 17 patients experienced dose-limiting toxicity at the 70 mg/m 2 dose level of oral vinorelbine. One patient experienced dose-limiting toxicity at a dose of 60 mg/m 2 and no dose-limitig toxicities were reported at the 50 mg/m 2 dose. The overall response rate by ≥50% reduction in PSA was 17.2%, (95% confidence interval, 5.9-35.8%). CONCLUSIONS Oral vinorelbine at doses of 70 mg/m 2 may be safely combined with estramustine. The combination appears to have modest activity in men with advanced prostate cancer. The trial design employed the time-to-event continual reassessment method, which potentially allows for rapid accrual, a more complete assessment of toxicities, and a larger fraction of patients to be treated at an effective dose. More active regimens are needed to further evaluate the utility of this clinical trial design in patients with prostate cancer. Cancer 2006. © 2006 American Cancer Society. | en_US |
dc.format.extent | 83836 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate Presented in part at the 39th annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30–June 3, 2003. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 615-2719 ; 7302 CCGC 0946, 1500 E. Medical Center Dr., Ann Arbor, MI 48109 | en_US |
dc.identifier.pmid | 16691618 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55222/1/21927_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.21927 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.